Presenting Phase 2a Results of ROSE-010 at Obesity Week 2025

PRESS RELEASE

Rose Pharma Inc. to Present Positive Phase 2a Results of ROSE-010 in Obesity at ObesityWeek® 2025

Poster presentation will highlight blinded, placebo-controlled data on mealtime food intake, caloric reduction, satiety, GI tolerability, safety, and weight loss

VIRGINIA BEACH, Va. — October 24, 2025 — Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at ObesityWeek® 2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m. ET in Atlanta, GA.

The poster presentation, titled “The Effect of the GLP-1 Agonist ROSE-010 on Food Consumption in Subjects with Overweight and Obesity: A Randomized Controlled Clinical Trial,” will share results from a blinded, placebo-controlled Phase 2a study evaluating multiple doses of ROSE-010 on mealtime food intake, caloric reduction, GI side effects, satiety, safety, and weight loss.

“We are excited to share additional data from our Phase 2a on ROSE-010 which continues to show strong potential as a differentiated approach to weight management for both induction and weight loss maintenance,” said Enda Kenny, CEO of Rose Pharma Inc. “These findings add to the growing need for improved tolerability of weight loss solutions to help people not only lose weight but keep their weight off by acting in a fast-onset, short-duration manner with very high tolerability.”

ObesityWeek® 2025 Presentation Details

Title: The Effect of the GLP-1 Agonist ROSE-010 on Food Consumption in Subjects with Overweight and Obesity: A Randomized Controlled Clinical Trial
Session: Poster Presentation
Date/Time: Tuesday, November 4, 2025 | 7:30 p.m. ET
Presenter: Enda Kenny, PhD, Chief Executive Officer, Rose Pharma Inc.
Location: ObesityWeek® 2025, Atlanta, GA (room/session ID to be announced)

About ROSE-010

ROSE-010 is a short-acting GLP-1 analogue designed for rapid onset and short duration of effect, enabling dosing timed to meal(s) of highest vulnerability to overeating. In Phase 2a clinical testing, ROSE-010 has demonstrated reductions in mealtime caloric intake and weight loss with a favorable GI tolerability profile, aligning with its limited exposure window. Beyond obesity and weight-loss maintenance, ROSE-010 has also shown clinically meaningful, statistically significant pain relief in a separate Phase 2a study of patients with irritable bowel syndrome (IBS), supporting its potential as the first targeted, on-demand therapy for acute IBS pain. Rose Pharma Inc holds patent protection around liquid and inhalable formulations and methods of use for GLP-1 analogs.

About Rose Pharma Inc.

Rose Pharma Inc. is a clinical-stage biopharmaceutical company advancing ROSE-010, a patented, short-acting GLP-1 analogue for weight management – particularly weight-loss maintenance – and acute IBS pain relief. The company’s strategy is to complete Phase 2 development to de-risk the asset for pivotal programs and pursue strategic partnerships for late-stage development and commercialization. Rose Pharma is incorporated in Delaware with operations in the United States. For more information, visit www.rosepharmainc.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding the potential safety, efficacy, clinical development, regulatory pathway, market opportunity, partnering strategy, and timing of presentations or future studies for ROSE-010. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including, without limitation: clinical development risks; the ability to obtain regulatory approvals; changes in applicable laws or regulations; reliance on third parties for manufacturing and other services; protection of intellectual property; competition; the company’s ability to raise additional capital; and other factors related to Rose Pharma’s industry, operations, and results. Rose Pharma undertakes no obligation to update any forward-looking statements except as required by law.

Business Contact
Lynn Sullivan, Chief Business Officer
Rose Pharma Inc.
info@rosepharmainc.com |